ישראל - עברית - Ministry of Health

novo nordisk ltd, israel - insulin aspart - תרחיף להזרקה - insulin aspart 100 iu/ml - insulin aspart - insulin aspart - treatment of diabetes mellitus.

ישראל - עברית - Ministry of Health

novo nordisk ltd., israel - insulin (human) - תרחיף להזרקה - insulin (human) 100 iu/ml - insulin (human) - insulin (human) - treatment of diabetes mellitus.

ישראל - עברית - Ministry of Health

novo nordisk ltd., israel - insulin (human) - תרחיף להזרקה - insulin (human) 100 iu/ml - insulin (human) - insulin (human) - treatment of diabetes mellitus.

ישראל - עברית - Ministry of Health

novo nordisk ltd., israel - insulin (human) - תרחיף להזרקה - insulin (human) 100 iu/ml - insulin (human) - insulin (human) - treatment of diabetes mellitus.

ישראל - עברית - Ministry of Health

novo nordisk ltd., israel - insulin (human) - תרחיף להזרקה - insulin (human) 100 iu/ml - insulin (human) - insulin (human) - treatment of diabetes mellitus.

ישראל - עברית - Ministry of Health

novo nordisk ltd., israel - insulin aspart - תרחיף להזרקה - insulin aspart 100 u/ml - insulin aspart - insulin aspart - treatment of diabetes mellitus.

ישראל - עברית - Ministry of Health

novo nordisk ltd - repaglinide 0.5 mg - tablets - repaglinide - treatment of type ii diabetes.

ישראל - עברית - Ministry of Health

novo nordisk ltd - repaglinide 1 mg - tablets - repaglinide - treatment of type ii diabetes .

ישראל - עברית - Ministry of Health

novo nordisk ltd - repaglinide 2 mg - tablets - repaglinide - treatment of type ii diabetes.

ישראל - עברית - Ministry of Health

novo nordisk ltd., israel - liraglutide - תמיסה להזרקה - liraglutide 6.0 mg/ml - liraglutide - liraglutide - for the treatment of adults with type 2 diabetes mellitus to achieve glycemic control : in combination with : - metformin or a sulphonylurea, in patients with insufficient glycemic control despite maximal tolerated dose of monotherapy with mentformin or sulphonylurea. - metformin and sulphonylurea or metformin and a thiazolidinedione in patients with insufficient glycemic control despite dual therapy.